Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.59 |
| ▸ | SKP1 | P63208 | 1/20 | 0.59 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.59 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28219652 | 0.93 | JAK3 (0.55) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL1588740 | 0.93 | JAK3 (0.55) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL16629090 | 0.93 | JAK3 (0.55) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL1427784 | 0.88 | EIF2AK4 (0.54) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL2273636 | 0.87 | CKS1B (0.60) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL15434052 | 0.87 | BTK (0.63) | SUV39H2PDE10AEIF2AK4JAK3BTK | |
| SCHEMBL3780868 | 0.86 | CKS1B (0.59) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL27665051 | 0.84 | CKS1B (0.61) | CKS1BSKP1SKP2SUV39H2PDE10A | |
| SCHEMBL6066402 | 0.84 | CKS1B (0.61) | CKS1BSKP1SKP2SUV39H2GPR119 | |
| SCHEMBL24851466 | 0.83 | CKS1B (0.54) | CKS1BSKP1SKP2SUV39H2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084865-A | Pyrimidine compound containing aminopiperidine structure, and preparation method and application thereof | 贵州大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-108822110-B | Aromatic heterocycle-containing a, β -unsaturated ketone compound and preparation method and application thereof | 山东大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-108822110-A | A containing aromatic heterocycle, alpha, beta-unsaturated ketone compound and the preparation method and application thereof | 山东大学 | 2018-11-16 | — | — | CN | disclosed |
| US-10023565-B2 | N,N′ substituted piperidinamine compounds, and preparation method and usage thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-07-17 | — | — | US | disclosed |
| US-10023565-B2 | N,N′ substituted piperidinamine compounds, and preparation method and usage thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-07-17 | — | — | US | disclosed |
| CN-108135175-A | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20160333002-A1 | N, N' SUBSTITUTED PIPERIDINAMINE COMPOUNDS, AND PREPARATION METHOD AND USAGE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-11-17 | — | — | US | disclosed |
| WO-2015138689-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015066696-A1 | FUSED MORPHLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479676-A1 | Benzimidazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | CKS1B 816/4885SKP1 1696/4885SKP2 1254/4885 |
| US-10023565-B2 | N,N′ substituted piperidinamine compounds, and preparation method and usage thereof | HSP90AB1, HSP90AB2P, HSF1 | CKS1B 4566/4885SKP1 441/4885SKP2 357/4885 |
| US-20160333002-A1 | N, N' SUBSTITUTED PIPERIDINAMINE COMPOUNDS, AND PREPARATION METHOD AND USAGE THEREOF | HSP90AB1, HSP90AB2P, HSF1 | CKS1B 4588/4885SKP1 431/4885SKP2 343/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | CKS1B 428/4885SKP1 1804/4885SKP2 2769/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CKS1B 995/4885SKP1 1249/4885SKP2 1248/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | CKS1B 958/4885SKP1 1826/4885SKP2 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.